Podcasts about VTE

Listen in to round out our conversation about anticoagulation, by hearing from two Anticoagulation Stewardship Pharmacists - Hadley Bortz from the Alfred in Melbourne and Julianne Chong from Concord Hospital. Find out more about ACS programs in Australia and overseas and the benefits that these programs can bring to your health service. Anticoagulant patient care plan Anticoagulation Forum Advancing Anticoagulation Stewardship: A Playbook CATAG Medicines Stewardship Toolkit 

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Send us a textThis episode reviews findings from a cross-sectional study at SickKids on health literacy in pediatric VTE patients and caregivers (Res Pract Thromb Haemost, 2025). Among 101 participants, 74% of adolescents and 59% of parents/caregivers demonstrated low general health literacy using REALM, HAS-A, and eHEALS instruments. Communication with providers was the most affected domain, and fewer than half of participants were satisfied with their thrombosis knowledge. Adolescents frequently overestimated their understanding, underscoring the need for simplified educational resources and a “universal precautions” approach to health literacy in pediatric thrombosis care.AboutKidsHealth Thrombosis Hub: https://www.aboutkidshealth.ca/thrombosisBastas, D., Mancini, A., Wong, G., Brandão, L. R., Mukaj, S., Vincelli, J., ... & Avila, L. (2025). Health literacy in pediatric thrombosis: a landscape analysis. Research and Practice in Thrombosis and Haemostasis, 9(1), 102653.Publication Link: https://www.rpthjournal.org/article/S2475-0379%2824%2900348-0/fulltextSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Cesarean Delivery: Major Abdominal SurgeryWelcome back to The Critical Care Obstetrics Podcast with hosts Suzanne McMurtry Baird (Nursing Director) and Stephanie Martin (Medical Director) of Clinical Concepts in Obstetrics.In this episode, we explore why cesarean delivery is not just another routine procedure—but truly a major abdominal surgery. While C-section is the most common surgical procedure performed in U.S. hospitals, its seriousness is often overlooked because of its frequency. We discuss:Why 1 in 3 births by cesarean should not normalize the risksThe role of evidence-based practices: avoiding the first cesarean, neuraxial anesthesia, infection prevention, and family-centered careWhat makes it a major surgery: open abdomen, incision types, considerations in obese patients, and classical cesarean challengesSafety for mothers, babies, and support persons in the ORCommon complications including VTE, infection and sepsis, blood loss, injury to other organs, and the rising risk of placenta accreta spectrumWe also highlight our new lecture in the Postpartum Course covering PACU care and Enhanced Recovery After Cesarean, including RN qualifications, complication management, and communication essentials.

In this episode, we talk with Dr. Christina Shenvi about ARIA, a finding associated with an early stage Alzheimer's infusion that can impact stroke and VTE care. The MRI of choice per neuroradiology are the T2 weighted and flare images seen on most routine head MRIs. The gradient recall echo are best for bleed and microhemorrhage. These are all part of a routine MRI. I would note in the order that you are looking for ARIA. Supported by Eli Lilly and Company

Send us a textIn this episode of CLOT Conversations, we discuss the newly developed Orthopedic Surgery VTE Thromboprophylaxis Guideline Summary. Dr. Marc Carrier, a hematologist and key author, highlights the need for a multidisciplinary approach in managing venous thromboembolism (VTE) risks, particularly in orthopedic surgery. The conversation covers preoperative risk assessments, options for pharmacological and mechanical thromboprophylaxis, and the evolving landscape of surgical techniques that influence thrombosis risk. The episode emphasizes the importance of providing clinicians with practical tools to effectively navigate VTE prevention.Access the full review paper here: https://thrombosiscanada.ca/uploads/publications/WhitePapers/TC135_VTE_Whitepaper_v4.pdfSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode of CLOT Conversations, experts discuss recent research on cancer-associated thrombosis and the predictors of recurrent venous thromboembolism (VTE) and anticoagulant-related bleeding. Dr. Faizan Khan, a leading researcher in the field, explains the results of their study that aimed to offer a comprehensive understanding of the prognostic factors associated with these risks. Hear what he says about the evidence for associations of several patient- and cancer-related factors, and the risk of recurrent VTE. This research is expected to inform clinical practice by promoting a more individualized approach to anticoagulant management in cancer patients.Reference: Khan, F., Tritschler, T., Marx, C. E., Lanting, V., Rochwerg, B., Tran, A., ... & Carrier, M. (2025). Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. European Heart Journal, ehaf453.https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf453/8170116?login=falseSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textDid you know that nearly 1 in 10 cancer patients worldwide may develop a potentially deadly blood clot? In this episode, we speak with researcher Jordan Harry, lead author of a landmark systematic review just published in Cancer Epidemiology, that uncovers which solid tumors carry the highest risk of venous thromboembolism (VTE) and where in the world patients are most vulnerable.Jordan walks us through surprising insights from their analysis of over 120 studies: 

Experts discuss effective communication strategies to empower patients of their options, set realistic expectations, and guide them towards informed decisions. Claim CE and MOC Credits at https://bit.ly/VTEComm

Send us a textIn this episode, our host Dr. Arjun Pandey (Internal Medicine Resident) interviews special guest Dr. Stefan Jevtic (Hematology Fellow) on hematologic conditions in pregnancy. They discuss the clinical presentation, investigations and management of thrombocytopenia, anemia, VTE and other hematologic conditions in pregnancy. Be sure to tune into www.cbcmadeeasy.com to reinforce your knowledge!Hosted by: Dr. Arjun Pandey (Internal Medicine Resident)Special Guest: Dr. Stefan Jevtic (Hematology Fellow)Produced by: Dr. Arjun Pandey and Dr. Zahra MeraliSupport the show

Send us a textIn this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this podcast episode, we explore groundbreaking research presented at the ISTH 2025 in Washington. Dr. Vicky May, Institut Universitaire de Cardiologie et Pneumologie de Québec, shares insights into a new diagnostic algorithm for pulmonary embolism (PE) in patients with chronic obstructive pulmonary disease (COPD). Her work focuses on identifying specific predictors, integrating these with established testing methods, and addressing challenges in the validation process. The discussion also highlights a study on recurrent venous thromboembolism (VTE), emphasizing symptom patterns and recurrence likelihood. These findings aim to refine clinical diagnostics, offering physicians refined tools for better patient management in thrombosis-related conditions.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode of Clot Conversations, hosts Jamil Abdulrehman, and Maha Othman interview Dr Stephanie Young from Memorial University in St John's, Newfoundland, at the 2025 ISTH meeting about her presentations on the complexities of patient experiences with Venous Thromboembolism (VTE). Dr Young shares findings from a qualitative study that highlight the uncertainties and emotional impacts patients face along their care journey. Key themes include the need for clearer care pathways, better access to specialized services, and greater involvement in decision-making. The discussion emphasizes integrating patient insights into clinical guidelines to enhance VTE care, aiming for a more patient-centered approach that accounts for both physical and psychological needs.Dr Young also references the Thrombosis Canada patient resources that can be found here: https://thrombosiscanada.ca/patients_and_caregiversSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Who/When to Treat Clinically Suspect Arthralgia Thoughtful, Effective RA Care Should be Guided by Need —Not Age The Impact of Biologics on Methotrexate Adherence Jokes Aside: The Impact of Laughter in RA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

Heart attacks & strokes are down, but guess what's rising? ⚡ Atrial fibrillation,

Deucravacitinib's Place in the PsA Treatment Algorithm? Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

In Nederland zijn we nogal van de directe communicatie. Maar hoe ga je om met een patiënt uit een andere culturele context die juist níet alles over haar diagnose wil weten? Jop praat erover met anios interne geneeskunde Rienke Fijn. Ethicus Pieter Jan Bougie vertelt wat een moreel beraad aan medisch personeel kan bieden in tijden van toenemende schaarste. De warme douche is voor het initiatief Wachtverzachters. Gerelateerde artikelenHet recht op niet-wetenEthiek in tijden van schaarsteLangdurige antistolling na VTE: minder is echt beterTwijfel over bewijs voor sonolyse bij CEA

In this podcast accompanying the June issue of DTB, David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor) and Laurence Leaver (GP). David and Julian start by discussing the editorial - https://dtb.bmj.com/content/63/6/82 - which highlights some of the challenges in preventing VTE in early pregnancy. They also talk about a cohort study - https://dtb.bmj.com/content/63/6/84 - that assessed whether gabapentinoid use was associated with severe exacerbations among patients aged >55 years with chronic obstructive pulmonary disease (COPD). In the second half of the podcast, Julian talks to Laurence about two articles - https://dtb.bmj.com/content/63/5/74 and https://dtb.bmj.com/content/63/6/85 - he wrote on managing ADHD in adults.   Their discussion includes issues relating to diagnosis, effectiveness of medication, starting and titrating medication and some of the common adverse effects associated with medication. Both articles are currently free to access on the DTB website.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

Vaginal oestrogen is safe at any age, including over 70, with regular review Use vaginal oestrogen cautiously in younger women; rule out other causes such like vulval dermatitis In breast cancer survivors, vaginal oestrogen is off-label; prefer estriol and involve oncology Vaginal DHEA (Intrarosa) is effective with minimal absorption; lacks long-term safety data; no washout needed when switching The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. What are the main symptoms for women with vaginal atrophy, and what is the general approach when a woman comes to talk about these symptoms? How long can women use vaginal oestrogen for? If you saw a woman over the age of 70, would you feel comfortable allowing her to continue using vaginal oestrogen? Is it safe to use vaginal oestrogen in a younger woman who might be breastfeeding or taking the combined oral contraceptive pill and experiencing vaginal dryness or discomfort? Do you need to take the same precautions for side effects as you would with systemic hormone therapy? For example, if there was a woman who was prone to venous thromboembolism (VTE), is it safe for her to use vaginal oestrogen? Is there any role for vaginal oestrogen in reducing the frequency of recurrent genital herpes outbreaks? Are there situations where you would use vaginal oestrogen in combination with a non-hormonal product for better results? Thoughts on laser treatments, microneedling, or PRP for vaginal or vulval symptoms? In women who present with urethral caruncles, is there a role for vaginal oestrogen as part of the treatment? How long would you try using vaginal oestrogen for that? What about the doses of oestrogen when treating someone who's had breast cancer? What do we have to be mindful of? What about women with a history of endometrial, cervical, or vulval cancer? Can we use vaginal oestrogen if they've got symptoms? Can DHEA (Intrarosa) be used safely in women with a history of cancer? For women without breast cancer, when would you use DHEA instead of oestrogen? Would you ever use both oestrogen and DHEA together? What about using DHEA in conjunction with systemic menopausal hormone therapy? Are there any thoughts around the improvements in libido with the use of DHEA? If you had tried someone on Ovestin (estriol) and wanted to switch to Intrarosa, is a washout period required before starting? Host: Dr Marita long | Total Time: 33 mins Expert: Dr Terri Foran, Sexual Health Physician Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

During this episode a panel of experts discuss the patient journey through the interpretation and application of safety and efficacy data to establish and maintain protocols designed to address optimal VTE treatment pathways. Claim CE and MOC Credit at bit.ly/VTEPJ6 

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

Send us a textIn this episode of CLOT Conversations, we sit down with Dr. Marc Carrier to explore a groundbreaking study published in the New England Journal of Medicine on reduced-dose apixaban for cancer-associated venous thromboembolism (VTE). Dr. Carrier breaks down the study's findings, which suggest that a lower dose of apixaban after six months of treatment is just as effective in preventing clot recurrence — and significantly safer in terms of bleeding risk. Tune in for expert insights on how this data could shift clinical practice and improve outcomes for patients living with cancer.Reference:Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, López-Núñez JJ, Otero-Candelera R. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 2025 Mar 29.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of pancreatic cancer. Drs. Rohit and Rahul Gosain are joined by Dr. Emil Lou, a medical and neuro-oncologist from the University of Minnesota, to discuss the challenges and advancements in managing this complex disease. In this episode, we covered: •⁠  ⁠The importance of a multidisciplinary approach in treating early-stage pancreatic cancer. •⁠  ⁠The role of neoadjuvant and adjuvant therapies, including the latest insights on chemotherapy regimens like FOLFIRINOX, nal-IRI and gemcitabine. •⁠  ⁠The significance of germline and next-generation sequencing (NGS) testing in personalizing treatment plans. •⁠  ⁠The current state of clinical trials and emerging therapies, including PARP inhibitors for BRCA mutations and the implications of ctDNA testing. •⁠  ⁠Prognostic discussions around metastatic pancreatic cancer and the importance of managing side effects to improve patient quality of life. Key takeaways include the necessity of balancing treatment efficacy with adverse events, the critical role of genetic testing, and the need for vigilance regarding venous thromboembolism (VTE) in pancreatic cancer patients. Don't miss this comprehensive discussion that aims to shed light on the ongoing efforts to improve outcomes for patients battling pancreatic cancer.   YouTube: https://youtu.be/HCKQxmOqRTI   Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more discussions on oncology and stay updated on the latest in cancer treatment!

In this episode, a panel of experts discuss existing and emerging VTE (venous thromboembolism) treatment options for the complex patient, such as a patient who has been diagnosed with cancer, end stage renal disease (ESRD), chronic kidney disease (CKD), or is obese.  Claim CE and MOC Credit at https://bit.ly/VTEHBCPX

For this episode we are joined by EBM guru, Dr. Brian Locke, who deftly breaks down all of our statistics questions. Is half dose DOAC as good as full dose DOAC for preventing VTE, and does it reduce bleeding risk? Can procalcitonin reduce duration of antibiotics for infections without compromising mortality rates? Can LLMs like GPT-4 help physicians manage patients better? Can reinforcement learning models predict when to start vasopressin in patients with septic shock? What is the risk of resuming anticoagulation in patients with atrial fibrillation and prior intracerebral hemorrhage? Is high flow nasal cannula as good as non-invasive ventilation for different types of respiratory failure? We answer all these questions and more!Half Dose DOAC for Long Term VTE Prevention (RENOVE)Biomarker-Guided Antibiotic Duration (ADAPT-Sepsis)GPT-4 Assistance for Physician PerformanceOptimal Vasopressin Initiation for Septic Shock (OVISS)DOACs for A fib after ICH (PRESTIGE-AF)High Flow Nasal Cannula vs NIV for Respiratory Failure (RENOVATE)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R

This week, we kick off a new, highly-anticipated and highly-requested series, covering venous thromboembolism (VTE). In this first episode, we discuss how we make the initial diagnosis and how we approach initial management. As a clinician, you will undoubtedly come across the need to make this decision. This episode and this series will set you up for success!Episode contents:-What is venous thromboembolism?- How do we diagnose patients with VTE?- How do we initially management patients with VTE? - How do we select anticoagulants for VTE? ****This episode is sponsored by our Global Research Partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Antithrombotic Therapy in VTE

  The RENOVE trial compared reduced-dose versus full-dose DOACs for extended venous thromboembolism VTE treatment in high-risk patients. While the reduced dose cut major bleeding risk by 39%

Concerned about VTE prevention in your facility? This episode explores how standardized protocols and technology can improve patient outcomes and operational efficiency. Join Dr. Parth Rali as he shares his experience at Temple University Hospital, including the creation of their Anticoagulation Stewardship Committee. You'll learn how standardizing care can lead to better decision-making and better results for patients. See References & Disclaimers.This episode is sponsored by Cardinal Health.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-vte-data-into-everyday-clinical-practice-for-ongoing-anticoagulation/32303/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-obesity-and-vte/32305/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-af-data-into-everyday-clinical-practice/32299/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/af-and-vte-global-considerations-in-the-evolving-space-of-real-world-data/32304/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/trade-off-ischemicthrombotic-vs-bleeding/32297/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implications-associated-with-integrating-both-real-world-data-and-clinical-trial-data-into-clinical-practice-af-considerations/32298/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-of-real-world-data-vs-rct/32296/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-elderly/32300/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-obesity/32301/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implications-associated-with-integrating-both-real-world-data-and-clinical-trial-data-into-clinical-practice-vte-considerations/32302/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

Venous Thromboembolism (VTE) is a condition where blood clots form in a blood vessel. As serious as heart attacks and strokes, VTE is the most common cause of preventable death in hospitalized patients. Interventional Radiologist Scott Perrin, MD, discusses the dangers of the disease and what can be done to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is responsible for 9–30% of pregnancy-related mortality in high resource countries and remains a significant, increasing cause of severe maternal morbidity. Peripartum, 50% of VTE events occur in the postpartum interval, which has a 6-fold higher risk compared to antepartum. There is wide variation in LMWH pharmacological postpartum prophylaxis guidance. The RCOG, for example, recommends 10 days of LMWH for all postop CS patients unless it was elective, and additional risk factors exist. The ACOG uses a more selective approach. However, on Jan 16, 2025, a new multicenter retrospective study from the US is raising questions about the efficacy of postpartum VTE pharmacologic therapy. Is there really no need for pp VTE pharmacologic therapy? Or does the answer lie in the reality of VTE as a “low frequency, high acuity” event? Listen in for details!

This week we discuss blood clots A blood clot is a clump of blood that has changed from a liquid to a gel-like or semisolid state. Clotting is a necessary process that can help prevent excessive blood loss when you have a cut, for example. Thrombosis is when a blood clot forms and reduces blood flow. There are two types: Arterial thrombosis occurs when a blood clot forms in an artery. Venous thrombosis occurs when a blood clot forms in a vein. When a clot forms inside one of your veins, it may dissolve on its own. However, sometimes a clot doesn't dissolve on its own, or part of it breaks off and travels elsewhere in your circulatory system. When this happens, the blood clot may get stuck elsewhere and restrict blood flow, known as embolism. These situations can be very dangerous and even life threatening. According to the Centers for Disease Control and Prevention (CDC), 1 in 2 people don't experience any symptoms when they have a deep venous blood clot. When symptoms do appear, it's important to get immediate medical attention. ​ Medical emergency A blood clot may be a medical emergency and life threatening if left untreated. Call 911 or go to the nearest emergency room immediately if you or someone you're with experiences symptoms of a serious blood clot, such as: sudden shortness of breath chest pressure difficulty breathing, seeing, or speaking ​Call a doctor or seek medical attention if you experience throbbing, swelling, and tenderness in one body part.  

Case Discussion 120: VTE prophylaxis

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Dr. Refaai  will help us understand the formation and function of fibrin monomers (FM) in hemostasis, highlighting their crucial role in coagulation and clot formation and the need for more prospective studies to validate this assay for clinical indications such as DIC, VTE and cancer. Literature sources: Refaai M.A. (2018) The Clinical Significance of Fibrin Monomers. Thromb Haemost, 118, 1856. Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Pulmonary emboli in Trauma patients is, unfortunately, an established and not uncommon complication we must deal with. Today, we welcome one of our own Trauma Surgeons, Dr Brent Emigh, MD to the Podcast to discuss VTE occurance and prophylaxis in Trauma patients. Article with more information on PE in Trauma patients is HERE Article mentioned on IVC filters can be accessed HERE If anyone has comments on this episode or suggestions for topics please feel free to reach out to me at kenneth_lynch@brown.edu

Everyone understands that VTE (DVT and/or VTE) requires life-saving anticoagulation. That's simple. No controversy there. But what about pregnancy-associated superficial thrombophlebitis (AKA superficial venous thrombosis) in an extremity? Does that need anticoagulation? We have been traditionally taught that superficial venous issues are benign and do not require LMWH. Is that correct? The answer is NOT as straightforward as you would think. In this episode, we will review the 2018 ASH guidelines and contrast them to the 2022 published consensus statement from the Balkan Working Group. Plus, we will highlight a May 2023 Danish population based study from the Lancet Hematology that reminds us that superficial venous disease is not always benign in its course. Listen in for details,

Proč se po soudních zaměstnancích rozhodli stávkovat i pražští zaměstnanci státních zastupitelstvích? Jak budou fungovat italská migrační centra v Albánii? Přispějí k řešení problému migrace do Evropy? A o čem jsou básně a hudba na novém studiovém albu Vladimíra Mišíka Vteřiny, měsíce a roky?

VTE prophylaxis is more than just some squeezy leg socks and a one-size fits all dose of enoxaparin!  Ever wonder how VTE prophylaxis is similar to constipation?  Have you or a loved one been hurt by a hospital administrator telling you that VTE is a never event?  Come with us, and our special guest Dr. Bryan Cotton, on this journey to the frontier of research attempting to debunk this myth and improve patient care by reducing VTE rates in trauma patients.   Hosts: - Michael Cobler-Lichter, MD, PGY4/R2: University of Miami/Jackson Memorial Hospital/Ryder Trauma Center @mdcobler (X/twitter) - Eva Urrechaga, MD, PGY-8, Vascular Surgery Fellow University of Pennsylvania Recent graduate of University of Miami/Jackson Memorial Hospital/Ryder Trauma Center General Surgery Residency @urrechisme (X/twitter) - Eugenia Kwon, MD, Trauma/Surgical Critical Care Attending: Loma Linda University Recent graduate of University of Miami/Jackson Memorial Hospital/Ryder Trauma Center Trauma/CC Fellowship - Brandon Parker, DO, Assistant Professor of Surgery, 5 years in practice University of Miami/Jackson Memorial Hospital/Ryder Trauma Center @BrandonParkerDO (X/twitter) - Bryan Cotton, MD, MPH, FACS, Professor of Surgery, 20 years in practice  University of Texas Health Science Center at Houston/Red Duke Trauma Institute at Memorial Herman Hospital @bryanacotton1 (X/twitter) Learning Objectives: - Describe the rationale for the addition of aspirin to chemoprophylactic regimens for VTE -  Identify appropriate screening systems for trauma patients at high risk for VTE -  Describe the rationale for monitoring anti factor Xa levels in the trauma population receiving VTE chemoprophylaxis - List the major conclusions of the two studies discussed regarding the addition of aspirin to VTE chemoprophylaxis regimens in trauma patients, and the change in antithrombin activity levels over time in relation to enoxaparin responsiveness in polytrauma patients Quick Hits: 1.     On adjusted analysis, the standard VTE PPX plus aspirin group had a lower OR of developing VTE, though limitations of this study highlight need for future prospective work 2.     Trauma patients often suffer from decreased activity of antithrombin 3, which may mediate the relatively higher rates of VTE in this population. 3.     Trauma patients who went on to develop VTE were more likely to not achieve satisfactory anti Xa levels, with a VTE rate of 30% in the never-responder group, the group for which Xa levels were never higher than 0.2 4.     Ex vivo supplementation of antithrombin seems to improve enoxaparin responsiveness.  Remember, enoxaparin and heparin are HELPING AT3, not the other way around References 1.     Lammers D, Scerbo M, Davidson A, et al. Addition of aspirin to venous thromboembolism chemoprophylaxis safely decreases venous thromboembolism rates in trauma patients. Trauma Surg Acute Care Open. 2023;8(1):e001140. doi:10.1136/tsaco-2023-001140 https://pubmed.ncbi.nlm.nih.gov/37936904/ 2.     Vincent LE, Talanker MM, Butler DD, et al. Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism. JAMA Surg. 2022;157(8):713-721. doi:10.1001/jamasurg.2022.2214 https://pubmed.ncbi.nlm.nih.gov/35731524/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen